Clinical trial
Prospective Multicenter Randomized Study of Ruxolitinib Plus Etanercept vs Ruxolitinib Alone for Corticosteroid-Refractory Severe Acute GVHD After Allogeneic HSCT
NCT07184853 is registered in ClinicalTrials.gov with First Affiliated Hospital of Zhejiang University as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Prospective Multicenter Randomized Study of Ruxolitinib Plus Etanercept vs Ruxolitinib Alone for Corticosteroid-Refractory Severe Acute GVHD After Allogeneic HSCT
- Lead sponsor
- First Affiliated Hospital of Zhejiang University
- Phase
- Not applicable
- Overall status
- Recruiting
- Start date
- September 25, 2025
- Completion date
- September 25, 2028
- Enrollment
- 122 (estimated)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.